Clinical trials: Cancer of the Esophagus
Unresectable Esophageal Cancer
Combination of Toripalimab and Chemoradiotherapy in Esophageal Cancer
Definitive chemoradiotherapy (CRT) is the standard treatment option for unresectable esophageal cancer (EC). However, as high as more than 40% of EC patients experienced locoregional recurrence after concurrent CRT.
- Trial name
- NCT04005170
- Testing
- Toripalimab, Paclitaxel/Cisplatin, Intensity-modulated radiotherapy
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Mian XI
Lung Cancer Metastatic, Renal Cell Carcinoma
Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO
Immunotherapy (IO), such as treatment with anti-PD-1, PD-L1, or CTLA-4 inhibitors, is a rapidly expanding treatment for multiple metastatic cancers with improved survival for certain cancers.
- Conditions
- Lung Cancer Metastatic, Renal Cell Carcinoma, Head and Neck Cancer, Triple Negative Breast Cancer
- Trial name
- MOIO (NCT05078047)
- Testing
- Reduced dose intensity of IO
- Where
- 33 sites in France
- Volunteers
- 646 people
- Sponsor
- UNICANCER
Esophageal Cancer
A Multicenter, Randomized Controlled, Phase II Clinical Study of First-line Chemotherapy and Camrelizumab With or Without Radiotherapy in the Treatment of Oligometastatic Esophageal Cancer
A multi-center, open, randomized controlled, phase II clinical study to evaluate the efficiency and safety of chemotherapy and immunotherapy combined with locol radiotharepy in treatment of patients with oligometastatic…
- Trial name
- NCT05183958
- Testing
- Radiotherapy group, Camrelizumab, Chemotherapy
- Where
- China
- Volunteers
- 118 people
- Sponsor
- Zhejiang Cancer Hospital
Esophageal Squamous Cell Carcinoma
PPIO-008 Tislelizumab Combined With S-1 in Patients With ypT+N0 ESCC After Radical Resection With Neoadjuvant STUDY
To explore the safety and efficacy of Tegafur combined with tislelizumab in patients with esophageal squamous cell carcinoma with residual primary lesion and node-negative after radical resection following neoadjuvant…
- Trial name
- NCT06354140
- Testing
- Tegafur
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma
Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.
Open-label, multi-center, non-randomized, multiple dose, safety, tolerability, pharmacokinetic, and pharmacodynamics and clinical activity study of PF-06940434 (Integrin alpha-V/beta-8 Antagonist) in patients with SCCHN (Squamous…
- Conditions
- Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Ovarian Cancer, Gastric Cancer
- Trial name
- NCT04152018
- Testing
- PF-06940434, PF-06801591
- Where
- 31 sites in United States, Australia and 3 more
- Volunteers
- 85 people
- Sponsor
- Pfizer
Advanced Esophageal Cancer
Study of SHR-1210 in Combination With Chemotherapy in Advanced Esophageal Cancer
This is a randomised, double-blinded, placebo-controlled, multi-center phase III trial, comparing the efficacy and safety of SHR-1210 + paclitaxel + cisplatin vs placebo+paclitaxel +cisplatin as 1L therapy for advanced esophageal…
- Trial name
- NCT03691090
- Testing
- SHR-1210, paclitaxel, cisplatin
- Where
- China
- Volunteers
- 596 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Atrial Fibrillation, Esophageal Carcinoma
Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer
This phase II trial studies how well amiodarone works in the prevention of atrial fibrillation (AF) after a minimally invasive esophagectomy (MIE) in patients with esophageal cancer.
- Trial name
- NCT06067438
- Testing
- Amiodarone Hydrochloride, Saline
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- OHSU Knight Cancer Institute
Liver Cancer Stage IV, Gastric Cancer Stage IV
To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor Affinity Enhancing Specific T Cell in Solid Tumors
The main purpose of this trial is to investigate the safety and tolerability of TAEST16001（TCR Affinity Enhancing Specific T cell Therapy）in the multi-line treatment failed advanced solid tumors except non small cell lung…
- Conditions
- Liver Cancer Stage IV, Gastric Cancer Stage IV, Esophageal Cancer, Stage IV, Bone and Soft Tissue Tumors
- Trial name
- NCT03159585
- Testing
- TAEST16001
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Zhujiang Hospital
Esophageal Cancer, Stomach Cancer
EUFURO - EUS-based Follow-Up on R0-resected Patients for Esophageal, Gastric and Pancreatic Cancer
Follow-up after successful operative treatment of cancer in the esophagus, stomach or pancreas in order to detect recurrent disease is a controversial topic.
- Conditions
- Esophageal Cancer, Stomach Cancer, Pancreatic Cancer
- Trial name
- EUFURO (NCT02209415)
- Testing
- standard follow-up, PET/CT and EUS
- Where
- Denmark
- Volunteers
- 182 people
- Sponsor
- Michael Bau Mortensen
Esophageal Squamous Cell Carcinoma
Trial of Nivolumab and Cetuximab After Chemoradiation in Esophageal Squamous Cell Carcinoma Patients.
This is a phase II, open label, two-centered study for evaluation of the addition of nivolumab and cetuximab after chemoradiation as a neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma patients.
- Trial name
- NCT04229459
- Testing
- Cisplatin, 5-FU, Radiation therapy
- Where
- Israel
- Volunteers
- 12 people
- Sponsor
- Baruch Brenner
Gastrointestinal Cancer
A Safety Study of TMV-018 in Patients With Tumors of the Gastrointestinal Tract
This study aims to determine the safety and tolerability of TMV-018 when given alone or in combination with the prodrug 5-Fluorocytosine (5-FC) or an anti-PD-1 checkpoint inhibitor in patients with gastrointestinal tumors.
- Trial name
- NCT04195373
- Testing
- TMV-018 + 5-FC, TMV-018 + anti-PD-1, TMV-018 + 5-FC + anti-PD-1
- Where
- 2 sites in Germany
- Sponsor
- Themis Bioscience GmbH
Breast Carcinoma, Colon Carcinoma
Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues
This phase I trial studies a new imaging technique called FAPi PET/CT to determine where and to which degree the FAPI tracer (68Ga-FAPi-46) accumulate in normal and cancer tissues in patients with non-prostate cancer.
- Conditions
- Breast Carcinoma, Colon Carcinoma, Esophageal Carcinoma, Gastric Carcinoma
- Trial name
- NCT04147494
- Testing
- Computed Tomography, Gallium Ga 68 FAPi-46, Gallium Ga 68-labeled PSMA-11
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Cancer of Stomach, Cancer of Esophagus
Audit of the Spanish EURECCA Esophagogastric Cancer Registry
Objective. The objective of the study is to verify and validate the data collected in the Spanish EURECCA (EUropean REgistry of Cancer CAre) Esophagogastric Cancer Registry between January 2014 and December 2017 through an audit…
- Trial name
- NCT03541629
- Where
- 11 sites in Spain
- Volunteers
- 1,839 people
- Sponsor
- Parc de Salut Mar
Esophageal Cancer
Radiotherapy,Chemotherapy,Before and After Surgery in Advanced Esophageal or Gastroesophageal Junction Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as cisplatin and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by…
- Trial name
- NCT00258323
- Testing
- cisplatin, fluorouracil, Iressa
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Case Comprehensive Cancer Center
Squamous Cell Esophageal Carcinoma, Esophageal Cancer
PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)
The primary objective is to compare PD-1 inhibitor combined with preoperative chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery, in terms of the overall survival time (OS) in patients…
- Conditions
- Squamous Cell Esophageal Carcinoma, Esophageal Cancer, Oesophageal Cancer
- Trial name
- NCT05357846
- Testing
- Sintilimab, Preoperative radiotherapy, Paclitaxel
- Where
- China
- Volunteers
- 422 people
- Sponsor
- Sun Yat-sen University
Minimal Residual Disease, Esophageal Squamous Cell Carcinoma
Efficacy Evaluation and Recurrence Monitoring of Therapy for Esophageal Squamous Cell Carcinoma Based on ctDNA-MRD.
This project is focusing on who have locally advanced esophageal squamous cell carcinoma and have undergone neoadjuvant and adjuvant therapy, followed by surgical resection.
- Trial name
- NCT05900583
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Guangdong Provincial People's Hospital
HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
This is a multicenter, global, Phase 2, open-label, 2-part, first-line study to investigate the safety, tolerability, and anti-tumor activity of ZW25 (zanidatamab) plus standard first-line combination chemotherapy regimens for…
- Trial name
- NCT03929666
- Testing
- ZW25 (Zanidatamab), Capecitabine, Cisplatin
- Where
- 23 sites in United States, Canada and 2 more
- Volunteers
- 74 people
- Sponsor
- Jazz Pharmaceuticals
Metastatic Esophageal Squamous Cell Carcinoma
Concurrent Chemoradiotherapy for Stage IVB Esophageal Squamous Cell Carcinoma（EC-CRT-003）
Retrospective studies suggested that the addition of thoracic concurrent chemoradiotherapy to systemic chemotherapy improved the survival and quality of life (QOL) of patients with metastatic esophageal squamous cell carcinoma…
- Trial name
- EC-CRT-003 (NCT05512520)
- Testing
- Intensity-modulated radiotherapy concurrent with capecitabine
- Where
- China
- Volunteers
- 126 people
- Sponsor
- Sun Yat-sen University
Esophageal Squamous Cell Carcinoma
Decitabine Plus Penpulimab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade
The purpose of this study is to observe and evaluate the efficacy and safety of Decitabine plus Penpulimab as second-line therapy for advanced esophageal squamous cell carcinoma treated with PD-1 blockade
- Trial name
- NCT05265962
- Testing
- Decitabine plus Penpulimab
- Volunteers
- 85 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Esophageal Squamous Cell Carcinoma
Neoadjuvant Sacituzumab Tirumotecan Plus Toripalimab in Locally Advanced Esophageal Squamous Cell Carcinoma
This study aims to evaluate the efficacy and safety of neoadjuvant sacituzumab tirumotecan (SKB264/MK-2870) combined with toripalimab in patients with locally advanced, resectable esophageal squamous cell carcinoma (ESCC).
- Trial name
- NCT07823270
- Testing
- Sacituzumab tirumotecan, Toripalimab
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Hebei Medical University Fourth Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.